Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.55 |
| ▸ | TUBB | P07437 | 6/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 6/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 6/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 6/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.55 |
| ▸ | ERN1 | O75460 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617954 | 0.86 | ERN1 (0.64) | HTTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29466480 | 0.86 | HTT (0.62) | HTTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL10316385 | 0.84 | HTT (0.57) | HTTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1618022 | 0.84 | HTT (0.60) | HTTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13356593 | 0.83 | HTT (0.56) | HTTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL17301353 | 0.82 | TUBB4A (0.62) | HTTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4114313 | 0.80 | ERN1 (0.68) | HTTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7430967 | 0.78 | CTSD (0.51) | HTTALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL28216057 | 0.78 | HTT (0.50) | HTTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL2764568 | 0.78 | HTT (0.50) | HTTTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394835-B2 | Aromatic compounds and their use in medical applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394835-B2 | Aromatic compounds and their use in medical applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394835-B2 | Aromatic compounds and their use in medical applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| EP-1732882-B1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| EP-1940372-B1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-11-09 | — | — | EP | disclosed |
| EP-1940372-B1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-20110152291-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1940372-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | Revotar Biopharmaceuticals AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007039113-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039113-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1764093-A1 | Novel aromatic compounds and their use in medical applications | Revotar Biopharmaceuticals AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764093-A1 | Novel aromatic compounds and their use in medical applications | Revotar Biopharmaceuticals AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1732882-A1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Revotar Biopharmaceuticals AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090284-A1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152291-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | SELP, SELL, SELE | HTT 1831/4885TUBB4A 2274/4885TUBB 2284/4885 |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | SELP, SELL, SELE | HTT 1715/4885TUBB4A 2209/4885TUBB 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.